CARDIOVASCULAR MEDICINE

Wine drinking is associated with increased heart rate variability in women with coronary heart disease

I Janszky, M Ericson, M Blom, A Georgiades, J-O Magnusson, H Alinagizadeh, S Ahnve

Heart 2005;91:314-318. doi: 10.1136/hrt.2004.035105

See end of article for authors' affiliations

Correspondence to:
Professor Staffan Ahnve,
Preventive Medicine,
Karolinska Institute,
Norrbäcka, 6th floor,
Karolinska Hospital, SE-
171 76 Stockholm,
Sweden; staffan.ahnve@
medhs.ki.se

Received 28 January 2004

Objective: To test the hypothesis that alcohol consumption is positively related to heart rate variability (HRV) in women with coronary heart disease (CHD) and therefore that cardiac autonomic activity is potentially implicated in the mediation of the favourable effects of moderate drinking.

Design, settings, and patients: Cross sectional study of female patients who survived hospitalisation for acute myocardial infarction or underwent a revascularisation procedure, percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting.

Main outcome measures: Ambulatory 24 hour ECG was recorded during normal activities. The mean of the standard deviations of all normal to normal intervals for all five minute segments of the entire recording (SDNNI) and the following frequency domain parameters were assessed: total power, high frequency power, low frequency power, and very low frequency power. A standardised questionnaire evaluated self reported consumption of individual alcoholic beverage types: beer, wine, and spirits. Other clinical characteristics, such as age, body mass index, smoking habits, history of diabetes mellitus, menopausal status, educational status, and treatment, were also assessed.

Results: Wine intake was associated with increased HRV in both time and frequency domains independently of other clinical covariates (for example, ln SDNNI was 3.89 among wine drinkers v 3.59 among wine non-drinkers in the multivariate model; $p = 0.014$). In contrast, consumption of beer and spirits and the total amount of alcohol consumed did not relate significantly to any of the HRV parameters.

Conclusion: Intake of wine, but not of spirits or beer, is positively and independently associated with HRV in women with CHD. These results may contribute to the understanding of the complex relation between alcohol consumption and CHD.

Compelling epidemiological evidence suggests that moderate intake of alcoholic beverages, especially wine, is associated with lower risk of coronary heart disease (CHD) morbidity and mortality.¹⁻⁴ Furthermore, moderate alcohol intake is related to reduced mortality after acute myocardial infarction (AMI).⁵⁻⁶ Mechanisms of this favourable effect of alcoholic beverages are not entirely clear; however, they may include increased high density lipoprotein cholesterol concentrations,⁷ improved coagulation profile,⁸⁻⁹ lower levels of inflammation,¹⁰ greater insulin sensitivity,¹¹ better endothelial function,¹² reduced endothelin 1 synthesis,¹³ low density lipoprotein oxidation,¹⁴ and smooth muscle proliferation.¹⁵⁻¹⁶

Heart rate variability (HRV), the amount of fluctuation of the beat to beat differences, is known to be a reliable, non-invasive marker of autonomic nervous system activity. Decrease in HRV has been found to predict CHD morbidity and mortality in apparently healthy populations¹⁷⁻¹⁸ and in patients after an acute coronary event.¹⁹⁻²³

Relatively few studies have examined the associations between drinking habits and HRV parameters, and the results are conflicting.²⁴⁻²⁹ The purpose of this study was to test the hypothesis that alcohol consumption is positively related to HRV in CHD and therefore that cardiac autonomic activity is potentially implicated in mediating the favourable effects of moderate drinking. We assessed total alcohol consumption, consumption of different types of alcoholic beverages, and time and frequency domain parameters of HRV by using ambulatory ECG monitoring in women with CHD.

METHODS

Study population

One hundred and two women, who survived hospitalisation for AMI or underwent a revascularisation procedure,

percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) at Huddinge University Hospital or St Göran's Hospital, Stockholm, Sweden, were enrolled. We based the diagnosis of AMI on World Health Organization criteria of typical enzyme patterns and chest pain or diagnostic ECG changes. Independently of the present report patients participated in a randomised controlled intervention trial. Consecutively, all eligible women below 75 years were asked to participate in the trial and those who agreed to do so were randomly assigned to either the control or the intervention group. The intervention comprised a stress management program specifically designed for women with CHD and targeted at improving social functioning, self esteem, and coping and decreasing depression and type A behaviour.³⁰

Ambulatory ECG monitoring and analyses of HRV

One year and five months (± 2.5 months) after randomisation a two channel ECG (Spacelab 90205; Spacelab Inc, Redmond, Washington, USA) was recorded over 24 hours during normal daily activities. The ECG electrodes were attached at the position of CM-V5 (left anterior axillary line sixth rib) and CS-V1 (fourth rib at the sternal border). Patients were asked to continue their usual medications.

The 24 hour Holter tape recordings were digitised and QRS labelled by a commercially available PC based system (Aspect Holter System, Daltek, Borlänge, Sweden). Arrhythmias were

Abbreviations: AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CHD, coronary heart disease; HRV, heart rate variability; PTCA, percutaneous transluminal coronary angioplasty; SDNNI, mean of the standard deviations of all normal to normal intervals for all five minute segments of the entire recording

automatically analysed and the QRS complexes classified. Consecutive RR intervals were expressed in centiseconds and analysed in units of five minute epochs by custom software. To be accepted for additional analysis, we required at least 96% of the QRS complexes to be classified as normal by the Aspect system.³¹ The time series of RR intervals were resampled at a frequency of two samples a second. Gaps in the time series due to non-normal RR intervals (QRS labelled by the Aspect System classification as noise or extrasystoles) were filled with values calculated by linear interpolation between adjacent normal RR intervals. Misclassified dropped beats deviating more than 3.0 SD from the normal RR interval of each epoch were also automatically checked.

Both time and frequency domain measures were analysed. The mean of the standard deviations of all normal to normal intervals for all five minute segments of the entire recording (SDNNI,³² in ms) was obtained from the time series of normal RR intervals. Frequency domain parameters were calculated by an autoregressive method as described previously³³: high frequency power, 0.15–0.40 Hz; low frequency power, 0.04–0.15 Hz; very low frequency power, 0.0033–0.04 Hz; and total power (in ms²).

Patients were not enrolled if they had non-sinus rhythm or if less than 50% of the original ECG recording was available for analysis.

Evaluation of alcohol consumption

Consumption of alcoholic beverages was assessed by the corresponding items of the Willett food frequency questionnaire,³⁴ which has shown excellent correlation with alcohol consumption as measured by four diet records of one week each (obtained 3–4 months apart) in a Swedish female cohort.³⁵ The questionnaire asks about the usual frequency and quantity of intake of five beverage types: regular beer, strong beer, wine, light spirits (for example, liqueur, vermouth, and port), and spirits. The estimated alcohol content of these beverages was 3.5%, 4.9%, 11%, 19%, and 39%, respectively. Average daily alcohol intake was calculated in grams. Daily consumption of alcohol was categorised as follows: 0 (abstainers), 0.1–5.0 g/day (light drinkers: up to half a standard drink a day), and > 5.0 g/day (moderate drinkers: over half a standard drink a day). Daily consumption of alcohol from regular beer, strong beer, wine, light spirits, and spirits was also calculated. Because overall consumption of strong beer and light spirits was low (mean intake 0.14 and 0.22 g/day, respectively), we grouped these beverages with regular beer and regular spirits, respectively, in beverage specific analyses. Binomial categorical variables were created to indicate whether patients consumed beer, wine, or spirits at all.

Other covariates

Educational attainment was classified into three levels: mandatory schooling only, completion of high school, and some college. Menopausal status was categorised as premenopausal, postmenopausal, taking hormone replacement therapy, and postmenopausal without hormone replacement therapy. Smoking status was categorised as never, current, or former smoking. Clinical history of diabetes mellitus was assessed. Height and weight were measured and body mass index was calculated.

Statistical analysis

HRV parameters were logarithmically transformed, as their distribution was skewed. Student's *t* test was used to detect significance of differences between continuous variables for two groups; one way analysis of variance was applied in the case of three groups. Categorical data were compared by χ^2 test.

Table 1 Clinical characteristics of the study group (n = 102)

Mean alcohol consumption (g/day)	1.62 (2.57)
Mean consumption of	
Beer (g/day)	0.61 (1.19)
Wine (g/day)	0.53 (1.16)
Spirits (g/day)	0.48 (1.11)
Heart rate variability	
ln SDNNI	3.81 (0.52)
ln total power	7.14 (1.16)
ln VLF power	6.36 (1.06)
ln LF power	5.85 (1.23)
ln HF power	5.62 (1.35)
Mean RR (ms)	897 (130)
Age (years)	64.3 (8.1)
Body mass index (kg/m ²)	26.5 (4.3)
Smoking	
Current	7.8%
Former	48.0%
Never	44.1%
Diabetes mellitus	20.6%
Menopausal status	
Premenopausal	8.9%
Postmenopausal on HRT	17.8%
Postmenopausal without HRT	73.3%
Educational attainment	
Mandatory	68.6%
High school	17.6%
College or university	13.7%
Medication use	
Aspirin	90.2%
Calcium channel blocker	24.5%
β Blocker	78.4%
ACE inhibitor	26.5%
Statins	77.5%
Index event*	
AMI	45.1%
CABG	38.2%
PTCA	36.3%
Stress management	53.9%

Continuous data are presented as mean (SD).

*Index event categories are not mutually exclusive.

ACE, angiotensin converting enzyme; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; HF, high frequency power; HRT, hormone replacement therapy; LF, low frequency power; PTCA, percutaneous transluminal coronary angioplasty; SDNNI, mean of standard deviations of all normal to normal intervals for all five minute segments of the entire recording; VLF, very low frequency power.

After adjustment for potentially confounding factors, least squares mean (SE) was calculated according to the general linear model for the parameters of HRV in each category of alcoholic beverage. Potential confounders were age, menopausal status, body mass index, smoking habits, educational status, history of diabetes mellitus, and treatment status (intervention versus control). In addition we adjusted for medications. Stratified analyses assessed possible effect modification. SAS version 8.2 (SAS Institute, Cary, North Carolina, USA) and SPSS version 11.0 for Windows (SPSS Inc, Chicago, Illinois, USA) were used for statistical analyses.

The study was approved by the ethics committee of Karolinska Institute at Huddinge University Hospital. Informed consent was obtained from all patients.

RESULTS

Table 1 presents the distribution of the study variables among women with complete data on HRV measurements and alcohol intake (n = 102).

HRV, heart rate, and alcohol consumption

Table 2 presents the HRV parameters and mean RR interval in the group of abstainers and light (0.1–5.0 g/day) and moderate (> 5.0 g/day) drinkers before and after adjustment. Although HRV parameters appeared to be higher with increasing alcohol intake, we found no significant

Table 2 Heart rate variability parameters and mean RR interval according to daily alcohol consumption

	Daily alcohol consumption (g/day)			p Value
	0 (n = 20)	0.1–5.0 (n = 76)	>5.0 (n = 6)	
ln SDNNI				
Unadjusted	3.68 (0.11)	3.83 (0.06)	3.91 (0.38)	0.48
Adjusted*	3.65 (0.18)	3.83 (0.13)	3.89 (0.25)	0.44
ln total power				
Unadjusted	6.90 (0.23)	7.19 (0.13)	7.31 (0.83)	0.57
Adjusted	6.87 (0.39)	7.20 (0.28)	7.31 (0.56)	0.54
ln VLF power				
Unadjusted	6.19 (0.21)	6.39 (0.12)	6.49 (0.63)	0.73
Adjusted	5.99 (0.36)	6.27 (0.26)	6.41 (0.51)	0.58
ln LF power				
Unadjusted	5.57 (0.25)	5.91 (0.13)	6.06 (0.94)	0.50
Adjusted	5.59 (0.42)	5.95 (0.30)	6.08 (0.59)	0.54
ln HF power				
Unadjusted	5.33 (0.26)	5.68 (0.15)	5.72 (0.99)	0.57
Adjusted	5.47 (0.45)	5.85 (0.33)	5.79 (0.65)	0.58
Mean RR				
Unadjusted	884 (28)	912 (14)	775 (51)	0.04
Adjusted	850 (39)	872 (28)	730 (55)	0.03

Data are mean (SE).

*Adjusted for age, menopausal status, body mass index, smoking habits, educational status, history of diabetes mellitus, and treatment status (intervention v control).

differences. However, mean RR interval was significantly differently distributed between the alcohol consumption categories; the highest values were registered among light drinkers.

HRV and consumption of specific alcoholic beverages

Table 3 presents the HRV parameters and mean RR interval according to the consumption of the three beverage types. Most of the HRV measures were significantly higher among women drinking wine in the unadjusted as well as in the adjusted models. HRV parameters also tended to be higher among beer drinkers and spirit drinkers than among women who did not drink beer or spirits, but these differences did not reach the level of significance. These findings remained essentially unchanged after further adjustment for β blockers and calcium channel blockers (ln SDNNI among wine drinkers and wine non-drinkers was 3.89 v 3.59, respectively,

in the model with further adjustment for medication, $p = 0.019$). Although mean RR interval was longer among wine drinkers ($p = 0.026$ and $p = 0.064$ for the unadjusted and adjusted models, respectively), adjusting for mean RR interval when testing the relation between wine drinking and HRV parameters gave similar results (for example, ln SDNNI was 3.92 v 3.68, $p = 0.043$ in the model with further adjustment for mean RR). Furthermore, we examined maximum heart rate as an indicator for physical activity during the 24 hour recording period and found no relation with wine intake and virtually no effect of adjustment.

To evaluate in more detail the relation of HRV to specific beverage intake, we also categorised consumption of beverage types as non-drinking, drinking below the median, and drinking above the median. ln SDNNI was 3.58 versus 3.96 versus 3.80 ($p = 0.025$, adjusted model) in these three groups of wine drinking, respectively. The other HRV

Table 3 Heart rate variability parameters and mean RR interval according to consumption of wine, beer, and spirits

	Daily consumption of alcoholic beverages (g/day)								
	Wine			Beer			Spirits		
	Yes (n = 69)	No (n = 33)	p Value	Yes (n = 52)	No (n = 50)	p Value	Yes (n = 54)	No (n = 48)	p Value
ln SDNNI									
Unadjusted	3.88 (0.07)	3.65 (0.07)	0.025	3.87 (0.07)	3.74 (0.07)	0.07	3.86 (0.07)	3.74 (0.07)	0.16
Adjusted*	3.89 (0.12)	3.59 (0.15)	0.014	3.87 (0.14)	3.76 (0.13)	0.30	3.88 (0.14)	3.74 (0.13)	0.21
ln total power									
Unadjusted	7.30 (0.15)	6.81 (0.16)	0.049	7.29 (0.16)	6.99 (0.16)	0.10	7.24 (0.17)	7.03 (0.16)	0.36
Adjusted	7.33 (0.28)	6.72 (0.33)	0.023	7.31 (0.31)	7.06 (0.29)	0.31	7.30 (0.30)	7.05 (0.30)	0.31
ln VLF power									
Unadjusted	6.50 (0.14)	6.06 (0.14)	0.062	6.43 (0.14)	6.28 (0.15)	0.24	6.46 (0.15)	6.24 (0.15)	0.18
Adjusted	6.41 (0.25)	5.80 (0.30)	0.014	6.30 (0.28)	6.21 (0.27)	0.66	6.40 (0.28)	6.11 (0.27)	0.22
ln LF power									
Unadjusted	6.02 (0.16)	5.49 (0.16)	0.035	6.02 (0.17)	5.67 (0.17)	0.07	5.98 (0.18)	5.70 (0.17)	0.32
Adjusted	6.09 (0.29)	5.44 (0.35)	0.024	6.08 (0.32)	5.79 (0.31)	0.25	5.77 (0.32)	6.07 (0.32)	0.27
ln HF power									
Unadjusted	5.78 (0.17)	5.27 (0.19)	0.089	5.84 (0.19)	5.38 (0.19)	0.06	5.67 (0.19)	5.56 (0.18)	0.75
Adjusted	5.96 (0.32)	5.37 (0.39)	0.059	6.05 (0.35)	5.61 (0.34)	0.12	5.89 (0.35)	5.72 (0.35)	0.56
Mean RR									
Unadjusted	918 (15)	857 (22)	0.026	906 (18)	890 (18)	0.51	891 (18)	906 (19)	0.55
Adjusted	872 (29)	821 (34)	0.064	871 (31)	849 (30)	0.39	852 (31)	864 (31)	0.63

Data are mean (SE).

*Adjusted for age, menopausal status, body mass index, smoking habits, educational status, history of diabetes mellitus, and treatment status (intervention v control).

parameters also differed significantly between the three groups, except for high frequency power, which was only marginally significant. However, there were no significant differences in HRV measures between the corresponding categories of consumption of spirits or beer.

Furthermore, we performed stratified analyses in selected clinical subgroups to ensure that our results were consistent. The results were not materially different when analyses were restricted to the control or to the intervention group, to patients ≥ 65 years or to patients < 65 years old, or to patients with AMI or patients who underwent CABG or PTCA.

We also tested the hypothesis that patients drinking beer or spirits may have a trend for higher HRV only due to their higher prevalence of wine drinking. When we simultaneously controlled for intake of other beverage types, wine intake remained significantly associated with HRV (ln SDNNI among wine drinkers was 3.61 and among non-drinkers, 3.89; $p = 0.041$, adjusted model). However, the tendency towards higher HRV among the consumers of beer and spirits was considerably attenuated in the simultaneous analyses (ln SDNNI 3.76 v 3.74, $p = 0.85$, and 3.76 v 3.73, $p = 0.86$, for drinkers versus non-drinkers of beer and spirits, respectively).

DISCUSSION

In this study of women with CHD we found that wine intake was associated with increased HRV independently of the potential confounding factors and of the intake of other beverages. In contrast, consumption of beer and spirits or the total amount of alcohol consumed did not relate significantly to any of the HRV parameters.

Convincing evidence suggests that alcohol consumption at moderate levels decreases CHD morbidity and mortality.¹⁻⁴ Moreover, recent studies found lower mortality after myocardial infarction among patients with moderate alcohol intake.⁵⁻⁶

Why moderate alcohol intake is associated inversely with CHD is not completely clear. A positive effect of alcohol on lipid profile is consistently reported. For instance, Langer and colleagues⁷ claimed that about half of the observed protection against CHD afforded by moderate alcohol consumption is mediated by an increase in high density lipoprotein. Other candidates for the favourable effect are decreased fibrinogen,⁸⁻⁹ decreased platelet activity,³⁶ lower levels of inflammation,¹⁰ greater insulin sensitivity,¹¹ better endothelial function,¹² reduced endothelin 1 synthesis,¹³ reduced low density lipoprotein oxidation,¹⁴ and smooth muscle proliferation.¹⁵⁻¹⁶ Given the compelling evidence that decreased HRV is an independent predictor of CHD mortality,¹⁷⁻²³ the present findings suggest that an increase in HRV may be a potential pathway for the protective effect of moderate alcohol consumption on CHD.

Whether the effect of moderate alcohol consumption on CHD is attributable to ethanol alone or if there are beverage specific differences is debated. In a recent review Gronbaek³⁷ concluded that wine drinkers are at a decreased risk of death from cardiovascular disease compared with non-wine drinkers, whereas other meta-analyses found that wine drinking confers no particular benefit.³⁸⁻³⁹ However, in this study wine was the only independent determinant of HRV among the alcoholic beverages, suggesting that only wine may have favourable effects mediated by this pathway.

Comparison with previous studies

According to previous observations acute alcohol intake decreases HRV, especially the indexes of vagal activity.⁴⁰⁻⁴³ It has also been shown that chronic excessive intake of alcohol is associated with decreased HRV.⁴⁴⁻⁴⁵

However, studies on usual daily alcohol consumption and HRV found varying and apparently opposite effects. Ryan and Howes²⁷ reported a negative relation between HRV and usual alcohol intake in apparently healthy men. In the Framingham study, Tsuji and colleagues²⁵ found a positive association between HRV and alcohol intake, but the association was no longer significant after controlling for potential determinants of HRV. In line with this finding alcohol was not a significant independent predictor in the studies of Virtanen and colleagues²⁸ and Stolarz and associates.²⁹ Nevertheless, according to Kupari and colleagues,²⁴ alcohol consumption is positively related to HRV in multivariate models in women, but not in men. All these studies examined apparently healthy people or population samples, except for the investigation of Virtanen and colleagues,²⁸ where patients with newly diagnosed hypertension were studied in addition to healthy volunteers.

Christensen and colleagues,²⁶ in a study population similar to ours, found that consumption of wine, but not beer, was associated with higher HRV among patients referred for coronary angiography. However, this effect was not independent of consumption of polyunsaturated fatty acids derived from fish, which was strongly related to HRV.

Study limitations

Several potential limitations of our study need to be considered, such as the use of self reported assessment of alcohol intake, which may lead to an underestimation of the real intake. However, there is no reason to believe that patients with lower HRV would underestimate their alcohol consumption to a greater extent.

The validity of our findings may be limited by the design of our study. As with any observational study, unevenly distributed characteristics associated with the amount of HRV may lead to overestimation or underestimation of the true effect of alcohol consumption. Multivariate adjustment here did not attenuate the association between wine intake and HRV. However, we cannot exclude the possibility of residual confounding, for example, by the effect of polyunsaturated fatty acids, which was a serious confounder in the study by Christensen and colleagues.²⁶ At the same time, a remaining confounder would need to be associated with both alcohol consumption and HRV and generally unrelated to the factors considered in our multivariate analyses.

The sample size may not have been sufficient in this study to detect an association between HRV and consumption of beer or spirits or total amount of alcohol consumed. Nevertheless, the association with wine intake was already significant at this level of statistical power, and the simultaneous analyses of the beverages types showed virtually no tendency for higher HRV among beer or spirit consumers.

Another potential limitation of the present study is the possibility that some women ceased drinking in response to the severity of their illness. Since we have no information on drinking habits in the past, the "sick quitter" hypothesis⁴⁶ may provide an alternative explanation for our findings.

We investigated women with established CHD and our findings are most readily generalised to similar populations. Women differ from men in drinking habits and alcohol metabolism, and recent studies suggest that wine drinking may have stronger effects on atherosclerosis in women.⁴⁷⁻⁴⁹ In addition, as alcohol consumption was rather modest among our patients we cannot extrapolate our results to heavier alcohol consumption.

Conclusion

Intake of wine, but not spirits or beer, was positively and independently associated with HRV in women with CHD. Our

results, suggesting that HRV may be an important linking factor, may contribute to the understanding of the complex relation of alcohol consumption with CHD.

ACKNOWLEDGEMENTS

This study was supported by grants from the Ansgarius Foundation, the Belvén Foundation, the Swedish Heart and Lung Foundation, the Public Health Committee and Expo-95 of Stockholm County Council, the Swedish Medical Research Council (project 19X-11629), and the Vardal Foundation, Stockholm, Sweden.

Authors' affiliations

I Janszky, M Blom, A Georgiades, H Alinagizadeh, S Ahnve, Preventive Medicine, Department of Public Health Sciences, Karolinska Institute, and Centre of Public Health, Stockholm County Council, Stockholm, Sweden

M Ericson, Department of Industrial Economics, Royal Institute of Technology, Stockholm, Sweden

J-O Magnusson, Department of Cardiology, St Görans Hospital, Stockholm, Sweden

Conflicts of interest: none.

REFERENCES

1. **Maclure M**. Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction. *Epidemiol Rev* 1993;**15**:328–51.
2. **St Leger AS**, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. *Lancet* 1979;*ii*:1017–20.
3. **Marmot MG**, Rose G, Shipley MJ, et al. Alcohol and mortality: a U-shaped curve. *Lancet* 1981;*ii*:580–3.
4. **Friedman LA**, Kimball AW. Coronary heart disease mortality and alcohol consumption in Framingham. *Am J Epidemiol* 1986;**124**:481–9.
5. **Mukamal KJ**, Maclure M, Muller JE, et al. Prior alcohol consumption and mortality following acute myocardial infarction. *JAMA* 2001;**285**:1965–70.
6. **Muntwyler J**, Hennekens CH, Buring JE, et al. Mortality and light to moderate alcohol consumption after myocardial infarction. *Lancet* 1998;**352**:1882–5.
7. **Langer RD**, Criqui MH, Reed DM. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. *Circulation* 1992;**85**:910–5.
8. **Mennen LJ**, Balkau B, Vol S, et al. Fibrinogen: a possible link between alcohol consumption and cardiovascular disease? DESIR study group. *Arterioscler Thromb Vasc Biol* 1999;**19**:887–92.
9. **Mukamal KJ**, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham offspring cohort. *Circulation* 2001;**104**:1367–73.
10. **Imhof A**, Froehlich M, Brenner H, et al. Effect of alcohol consumption on systemic markers of inflammation. *Lancet* 2001;**357**:763–7.
11. **Kiechl S**, Willeit J, Poewe W, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study. *BMJ* 1996;**313**:1040–4.
12. **Cuevas AM**, Guasch V, Castillo O, et al. A high-fat diet induces and red wine counteracts endothelial dysfunction in human volunteers. *Lipids* 2000;**35**:143–8.
13. **Corder R**, Douthwaite JA, Lees DM, et al. Endothelin-1 synthesis reduced by red wine. *Nature* 2001;**414**:863–4.
14. **Nigdikar SV**, Williams NR, Griffin BA, et al. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. *Am J Clin Nutr* 1998;**68**:258–65.
15. **Iijima K**, Yoshizumi M, Hashimoto M, et al. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene. *Circulation* 2000;**101**:805–11.
16. **Hendrickson RJ**, Cahill PA, McKillop IH, et al. Ethanol inhibits mitogen activated protein kinase activity and growth of vascular smooth muscle cells in vitro. *Eur J Pharmacol* 1998;**362**:251–9.
17. **Dekker JM**, Schouten EG, Klootwijk P, et al. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. *Am J Epidemiol* 1997;**145**:899–908.
18. **Tsuji H**, Venditti FJ, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort: the Framingham heart study. *Circulation* 1994;**90**:878–83.
19. **Kleiger RE**, Miller JP, Bigger JT, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* 1987;**59**:256–62.
20. **Bigger JT**, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. *Circulation* 1992;**85**:164–71.
21. **Quintana M**, Storck N, Lindblad LE, et al. Heart rate variability as a means of assessing prognosis after acute myocardial infarction: a 3-year follow-up study. *Eur Heart J* 1997;**18**:789–97.
22. **La Rovere MT**, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (autonomic tone and reflexes after myocardial infarction) investigators. *Lancet* 1998;**351**:478–84.
23. **Huikuri HV**, Makikallio T, Peng CK, et al. Fractal correlation properties of RR interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. *Circulation* 2000;**101**:47–53.
24. **Kupari M**, Virolainen J, Koskinen P, et al. Short-term heart rate variability and factors modifying the risk of coronary artery disease in a population sample. *Am J Cardiol* 1993;**72**:897–903.
25. **Tsuji H**, Venditti FJ Jr, Manders ES, et al. Determinants of heart rate variability. *J Am Coll Cardiol* 1996;**28**:1539–46.
26. **Christensen JH**, Skou HA, Fog L, et al. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. *Circulation* 2001;**103**:651–7.
27. **Ryan JM**, Howes LG. Relations between alcohol consumption, heart rate, and heart rate variability in men. *Heart* 2002;**88**:641–2.
28. **Virtanen R**, Jula A, Kuusela T, et al. Reduced heart rate variability in hypertension: associations with lifestyle factors and plasma renin activity. *J Hum Hypertens* 2003;**17**:171–9.
29. **Stolarz K**, Staessen JA, Kuznetsova T, et al. Host and environmental determinants of heart rate and heart rate variability in four European populations. *J Hypertens* 2003;**21**:525–35.
30. **Burell G**, Granlund B. Women's hearts need special treatment. *Int J Behav Med* 2002;**9**:228–42.
31. **Nygårds ME**. An automated system for ECG monitoring. *Comput Biomed Res* 1978;**12**:181–202.
32. **Anon**. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation* 1996;**93**:1043–65.
33. **Janszky I**, Ericson M, Mittleman MA, et al. Heart rate variability in long-term risk assessment in middle aged women with coronary heart disease: the Stockholm female coronary risk study. *J Intern Med* 2004;**255**:13–21.
34. **Willett WC**, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. *Am J Epidemiol* 1985;**122**:51–65.
35. **Larsson SC**, Giovannucci E, Wolk A. Dietary folate intake and incidence of ovarian cancer: the Swedish mammography cohort. *J Natl Cancer Inst* 2004;**96**:396–402.
36. **Rubin R**. Effect of ethanol on platelet function. *Alcohol Clin Exp Res* 1999;**23**:1114–8.
37. **Gronbaek M**. Alcohol, type of alcohol, and all-cause and coronary heart disease mortality. *Ann N Y Acad Sci* 2002;**957**:16–20.
38. **Rimm EB**, Klatsky A, Grobbee D, et al. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits? *BMJ* 1996;**312**:731–6.
39. **Cleophas TJ**. Wine, beer and spirits and the risk of myocardial infarction: a systematic review. *Biomed Pharmacother* 1999;**53**:417–23.
40. **Koskinen P**, Virolainen J, Kupari M. Acute alcohol intake decreases short-term heart rate variability in healthy subjects. *Clin Sci (Lond)* 1994;**87**:225–30.
41. **Rossinen J**, Viitasalo M, Partanen J, et al. Effects of acute alcohol ingestion on heart rate variability in patients with documented coronary artery disease and stable angina pectoris. *Am J Cardiol* 1997;**79**:487–91.
42. **Bennett AJ**, Sponberg AC, Graham T, et al. Initial ethanol exposure results in decreased heart rate variability in ethanol-naïve rhesus monkeys. *Eur J Pharmacol* 2001;**433**:169–72.
43. **Minami J**, Todoroki M, Ishimitsu T, et al. Effects of alcohol intake on ambulatory blood pressure, heart rate, and heart rate variability in Japanese men with different ALDH2 genotypes. *J Hum Hypertens* 2002;**16**:345–51.
44. **Malpas SC**, Whiteside EA, Maling TJ. Heart rate variability and cardiac autonomic function in men with chronic alcohol dependence. *Br Heart J* 1991;**65**:84–8.
45. **DePetrillo PB**, White KV, Liu M, et al. Effects of alcohol use and gender on the dynamics of EKG time-series data. *Alcohol Clin Exp Res* 1999;**23**:745–50.
46. **Shaper AG**, Wannamethee G, Walker M. Alcohol and mortality in British men: explaining the U-shaped curve. *Lancet*, 1988;*ii*, 1267–73.
47. **Di Castelnuovo A**, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. *Circulation* 2002;**105**:2836–44.
48. **Klatsky AL**, Friedman GD, Armstrong MA, et al. Wine, liquor, beer, and mortality. *Am J Epidemiol* 2003;**158**:585–95.
49. **Reynolds K**, Lewis B, Nolen JD, et al. Alcohol consumption and risk of stroke: a meta-analysis. *JAMA* 2003;**289**:579–88.